Transfusion Dependent Thalassaemia Management Market Snapshot (2023 to 2033)
The global Transfusion Dependent Thalassaemia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Transfusion Dependent Thalassaemia Management registered a CAGR of 4% in the historical period 2018 to 2022.
Studies state that Thalassemia affects approximately 4.4 out of every 10,000 live births throughout the world. This condition causes both males and females to inherit the relevant gene mutations equally because it follows an autosomal pattern of inheritance with no preference for gender.
Report Attribute
Details
Expected Market Value (2023)
US$ 10 Million
Anticipated Forecast Value (2033)
US$ 17.91 Million
Projected Growth Rate (2023 to 2033)
6% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Transfusion Dependent Thalassaemia Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Transfusion Dependent Thalassaemia Management reflected a value of 4% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering effective ways for Transfusion Dependent Thalassaemia Management.
According to the National Center on Birth Defects and Developmental Disabilities, thalassemia affects at least 1,000 people in the United States of America. The market's growth is also attributed to the factors such as growing disease prevalence, a rise in lifestyle-associated concerns, and technological advancements. Furthermore, the increasing incidence of thalassemia patients and increasing research and development investments are propelling immense growth.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for Transfusion Dependent Thalassaemia Management. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of thalassemia is fuelling market growth. Thus, the market for Transfusion Dependent Thalassaemia Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Transfusion Dependent Thalassaemia Management Market?
Increased Prevalence of the Condition to Push the Market Growth
According to the Thalassemia International Federation, approximately 7.0% of the global population suffers from diseases and conditions associated with hemoglobin, out of which around 70.0% have sickle cell anemia and the remaining develop thalassemia or other blood disorders. Around 2.1% of the global population is living with various forms of thalassemia. This disorder affects approximately 4.4 in every 10,000 live births worldwide.
Blood transfusion is one of the conventional treatments for thalassemia patients involving patients that need more than 2 units of red blood cells every 28 days. Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting market growth. Government measures to raise thalassemia awareness are also expected to propel the market in the next few years.
For instance, in March 2022, CIL inked an MoU with the Kokilaben Dhirubhai Ambani for its primary program Thalassemia Bal Seva Yojana, which would fund bone marrow transplants for Thalassemia and Aplastic Anaemia patients from low-income families. This initiative gives financial support of up to ten lakh rupees to children of low-income families suffering from Thalassemia and Aplastic Anaemia. This, in turn, is expected to have a significantly positive impact on the market's growth.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Transfusion Dependent Thalassaemia Management Market?
Expensive Cost of Treatment to restrict Market Growth
According to the Centers for Disease Control, people who receive a lot of blood transfusions are at risk for iron overload. Red blood cells contain a lot of iron, and over time, the iron from all of the transfusions can build up in the body. When it builds up, the iron collects in places like the heart, liver, and brain, and can make it hard for these organs to work properly. To prevent iron overload, people with thalassemia may need chelation therapy, which is when doctors give a medicine - either a pill or a shot under the skin - to remove excess iron before it builds up in the organs. Considering this, the market growth is projected to get hampered.
The expensive treatment of Transfusion Dependent Thalassaemia Management, less awareness of Fucosidosis disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Region-Wise Insights
How is the Market for Transfusion Dependent Thalassaemia Management Market Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling the growth of Transfusion Dependent Thalassaemia Management in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Transfusion Dependent Thalassaemia Management Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. The increasing number of hospitals in India and China makes a promising market for the market worldwide.
In November 2020, for instance, researchers from numerous educational institutions based in China conducted a study to evaluate the prevalence of iron deficiency anemia and anemia in pregnant women. They found that nearly 13.9% of Chinese women were diagnosed with iron deficiency anemia, while around 19.8% were diagnosed with anemia. The increasing number of similar research studies in this country is anticipated to fuel the market.
What are the Factors Boosting the Market for Transfusion Dependent Thalassaemia Management in North America?
Technological Advancements Shaping Landscape for Transfusion Dependent Thalassaemia Management in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. As per the American Family Physician, the prevalence of iron deficiency anemia is about 20% in black and Mexican-American women, 9 to 12% in non-Hispanic white women, and nearly 2% in adult men. Approximately 9% of patients older than 65 years with this condition have gastrointestinal cancer. These numbers are estimated to grow in the near future, thereby propelling the market growth.
Government initiatives and an increase in the number of research partnerships are boosting market growth across North America. The United States of America leads the regional market owing to the rising awareness about the condition and the increasing number of populations with thalassemia carrier gene along with expanding birth rates due to variation of genes among the population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Treatment, Which Segment is Likely to Account for a Prominent Share?
Iron Chelating Drugs as an effective treatment to drive the market
According to the FMI analysis, the Increasing incidence of iron deficiency among individuals is expected to continue driving sales for iron chelating drugs over the forecast period. The increasing popularity of these drugs as an effective treatment along with the presence of innovative technologies and changing lifestyle patterns are other crucial factors augmenting the demand.
In May 2020, Luspatercept was suggested for authorization by the Committee for Medicinal Products for Human Use (CHMP) to treat anemia in both the rare blood condition beta type and the hematological malignancy myelodysplastic syndrome (MDS). Apart from this, some of the other approved chelating drugs in the USA include succimer, dimercaprol (BAL), edetate calcium disodium, deferoxamine, and penicillamine.
By End-user, Which Segment is Likely to Account for a Significant Share?
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the Transfusion Dependent Thalassaemia Management facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases. The ability of doctors to provide customers with personalized advice that would pertain to their specific circumstances and health needs will boost growth.
Market Competition
Key players in the Transfusion Dependent Thalassaemia Management Market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
In November 2022, the Centers for Disease Control and Prevention (CDC) launched a Thalassemia Healthcare Provider Resource Toolkit. This free toolkit is filled with free resources for providers caring for people living with thalassemia. It includes Continuing Medical Education Offerings and Webinars, Scientific Articles and Features, CDC Activities Related to Transfusion Complications in Thalassemia, Resources on Newborn Screening, Thalassemia Treatment Centers, Resources for Thalassemia Care, Treatment, and Management, and so on.
In August 2022, the USA Food and Drug Administration approved Zynteglo (Betibeglogene auto excel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 10 Million
Market Value in 2033
US$ 17.91 Million
Growth Rate
CAGR of 6% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Treatment
End-User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Argentina
Germany
United Kingdom
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
Association of Southeast Asian Nations
Gulf Cooperation Council
South Africa
Key Companies Profiled
Sigma-Aldrich. BD
Enzo Life Sciences
Creative Diagnostics
Thermo Fisher Scientific
Epitope Diagnostics Inc.
R&D Systems
QED Bioscience Inc
ACROBiosystems.
Customization
Available Upon Request
Key Segments Profiled in the Transfusion Dependent Thalassaemia Management Industry Survey
Therapy:
Iron Chelating Drugs
Erythroid Maturation Agents
Stem Cell Therapy
Others
End-User:
Hospital
Homecare
Specialty Clinics
Others
Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
How the Gas Insulated Substation Market Developed in the Past?
From 2018 to 2022, the global market exhibited a 5.4% CAGR.
What is the Projected Size of the Transfusion Dependent Thalassaemia Management Market by 2033?
The global market size is estimated to reach US$ 17.91 billion by 2033.
Who are the Top Key Players in the Transfusion Dependent Thalassaemia Management Market?
R&D Systems and Creative Diagnostics are the top key players.
What is the Growth Potential of the Transfusion Dependent Thalassaemia Management Market?
The global market is estimated to secure a CAGR of 6% through 2033.
What Limits the Growth Potential of the Transfusion Dependent Thalassaemia Management Market?
Expensive treatment costs are likely to limit market growth.
Table of Content
1. Executive Summary | Transfusion Dependent Thalassaemia Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Iron Chelating Drugs
5.3.2. Erythroid Maturation Agents
5.3.3. Stem Cell Therapy
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End Users
11.4. Key Takeaways
12. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End Users
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Celgene Corp.
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. BlueBird Bio
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Protagonist Therapeutics
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Agios Pharmaceuticals
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Ionis Pharmaceuticals
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Vifor Pharma
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Sangamo Therapeutics
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Orchard Therapeutics
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. CRISPR Therapeutics
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. DisperSol Technologies
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 4: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 7: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 10: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 13: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 16: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Value (US$ Million) Forecast by End Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Value (US$ Million) by End Users, 2023 to 2033
Figure 3: Global Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 11: Global Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 12: Global Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 13: Global Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Attractiveness by End Users, 2023 to 2033
Figure 15: Global Attractiveness by Region, 2023 to 2033
Figure 16: North America Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Value (US$ Million) by End Users, 2023 to 2033
Figure 18: North America Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 28: North America Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Attractiveness by End Users, 2023 to 2033
Figure 30: North America Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Value (US$ Million) by End Users, 2023 to 2033
Figure 33: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 41: Latin America Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 42: Latin America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 43: Latin America Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Attractiveness by End Users, 2023 to 2033
Figure 45: Latin America Attractiveness by Country, 2023 to 2033
Figure 46: Europe Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Value (US$ Million) by End Users, 2023 to 2033
Figure 48: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 56: Europe Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 57: Europe Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 58: Europe Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Attractiveness by End Users, 2023 to 2033
Figure 60: Europe Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Value (US$ Million) by End Users, 2023 to 2033
Figure 63: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 71: Asia Pacific Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 72: Asia Pacific Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 73: Asia Pacific Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Attractiveness by End Users, 2023 to 2033
Figure 75: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 76: MEA Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Value (US$ Million) by End Users, 2023 to 2033
Figure 78: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 86: MEA Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 87: MEA Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 88: MEA Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Attractiveness by End Users, 2023 to 2033
Figure 90: MEA Attractiveness by Country, 2023 to 2033
